About Tarsus Rx
Tarsus Rx is a publicly listed company based in Irvine (United States) founded in 2017, and was acquired by Portage Biotech in July 2022. Proprietary drugs for blepharitis treatment are developed by Tarsus. Tarsus Rx has raised $60 million across 1 funding round from investors including Frazier Healthcare Partners, Portage Biotech and Vivo Capital. The company has 323 employees. Its chief executive, as recorded, is Bobak Azamian. Its website tarsusrx.com draws about 45 thousand monthly visits. Tarsus Rx offers products and services including XDEMVY, TP-04, and TP-05. Its focus areas include Life Sciences, Ophthalmology, Drugs and Blepharitis. Its legal entity is TARSUS PHARMACEUTICALS, INC.
Company details
Tarsus was founded in 2017 and is headquartered in Irvine, United States. Focus is placed on the pharmaceutical sector, specifically ophthalmology, where proprietary drugs for eye conditions are developed. The lead candidate, TP-03, a topical ophthalmic treatment for Demodex blepharitis, is advancing through Phase 2b3 clinical trials. Additional pipeline efforts target other ocular disorders, with operations centered on drug innovation and testing.
- Headquarters Irvine, United States
- Employees 323
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website tarsusrx.com
- Social LinkedIn X Facebook Instagram
- Acquired by Portage Biotech (Jul 2022)
- Legal Name Tarsus Pharmaceuticals, Inc.
- Annual Revenue$451.36 M (USD)146.71as on Dec 31, 2025
- Net Profit-$66.42 M (USD)42.52as on Dec 31, 2025
- EBITDA-$69.15 M (USD)42.06as on Dec 31, 2025
- Total Equity Funding$60M (USD)
in 1 rounds
- Latest Funding Round$60M (USD), Series B
Jan 2020
- InvestorsFrazier Healthcare Partners
& 6 more
- Employee Count323
- Acquired byPortage Biotech
(Jul 2022)
Products & Services of Tarsus Rx
Tarsus Rx offers a comprehensive portfolio of products and services, including XDEMVY, TP-04, and TP-05.
FDA-approved treatment for Demodex blepharitis eye condition
Potential treatment for ocular rosacea inflammatory condition
Investigational option for preventing Lyme disease transmission
Funding Insights of Tarsus Rx
Tarsus Rx has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series B round of $60 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60M
- Total Rounds 1
- Last Round Series B — $60M
- First Round $60M
(Jan 2020)
- Investors Count 6
All 1 funding rounds of Tarsus Rx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $60M | Series B | – | Vivo Capital |
7 investors in total: 7 institutional.
Investors in Tarsus Rx
Tarsus Rx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, Portage Biotech and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Flying L Partners is focused on ophthalmic sector investments. | flyinglpartners.com | |||
A venture capital fund focused on life sciences investments. | 2019 | visionaryvc.com | Newport Beach, United States | |
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
Horowitz Group is operated as a single family office in Southern California. | horowitzgroup.com | Newport Beach, United States | ||
Therapeutics based on Cell Permeable Peptide Platform | 2013 | portagebiotech.com | Tortola, United Kingdom |
Investor details for Tarsus Rx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tarsus Rx
144 people are tracked at Tarsus Rx (61 in leadership, 7 in board & advisors, 76 in team); the tracked headcount is 323.
| Name | Role | Group |
|---|---|---|
Bobak Azamian | CEO | Leadership |
Kurt Turner | Senior Director, Market Access Strategy And Pricing Operations | Leadership |
Darryl Fairley | Sales Director At Tarsus | Leadership |
Jack Cui | Director, Sourcing And Procurement | Leadership |
Ashley Gonzalez | Associate Director Of Business Development | Leadership |
Leila N. | Director, Human Resources | Leadership |
Dianne Whitfield | Chief Human Resources Officer | Leadership |
Ravindra K. | Head, Gxp IT Systems | Leadership |
Anna George | Associate Director, Planning, Forecasting & Analytics | Leadership |
Marca Clark | Director, Talent Development | Leadership |
Adrienne Kemp | Senior Director, Corporate Communications | Leadership |
Joanna Tong | Associate Director, Supply Chain | Leadership |
Corey Wolfe | Regional Sales Director; West | Leadership |
Scott Youmans | VP, Sales | Leadership |
Jerry Williamson | Associate Director Sales Effectiveness | Leadership |
Elizabeth Da Silva | VP, Regulatory Affairs | Leadership |
Esteban Nocito | Sr. Director, Payer Accounts | Leadership |
Jeff Farrow | CFO & Chief Strategy Officer | Leadership |
Mark Luz | VP, Strategy & Commercial Ops | Leadership |
Maria Spielberger | Associate Director, Compliance | Leadership |
124 more people are available in the full profile.
Complete people profiles for Tarsus Rx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tarsus Rx
Tarsus Rx is a publicly listed company on the NASDAQ with ticker symbol TARS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2020
- Listed onNASDAQ: TARS
- Listed entityTarsus Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS87650L1035
- Share price$70.82 (-4.81% on the day) · 2026-10-13
- Market capitalisation$3.31B
- EPS (diluted, trailing year)$-1.08
- Volume (last session)1,632,816
Financials of Tarsus Rx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $451.4M | -$66.4M | -$69.2M |
| 2024 | $182.9M | -$115.5M | -$119.3M |
| 2023 | $17.4M | -$135.9M | -$142.3M |
| 2022 | $25.8M | -$62.1M | -$61.9M |
| 2021 | $57.0M | -$13.8M | -$11.6M |
Detailed financial statements for Tarsus Rx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Tarsus Rx
4 dated milestones of Tarsus Rx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Tarsus Rx is founded.
- Funding First funding round of $60.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Portage Biotech.
Web traffic of Tarsus Rx
The website of Tarsus Rx (tarsusrx.com) receives about 45.5K visits a month and ranks #735,192 among all websites worldwide, #842 in Biotechnology and Pharmaceuticals.
- Monthly visits45.5K
▲ 57.6% vs previous month
- Unique visitors9.4K
per month
- Global rank#735,192
among all websites
- Category rank#842
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit4.6
- Average visit2 min 48 sec
- DevicesDesktop 70% · Mobile 30%
Websites whose visitors overlap most with Tarsus Rx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biotechtv.com | biotechtv.com | 100% | #1,035,133 | – | |
pharmexec.com | pharmexec.com | 100% | #565,102 | – | |
pharmavoice.com | pharmavoice.com | 100% | #720,985 | – | |
xdemvy.com | xdemvy.com | 87% | #180,049 | – | |
contactlensupdate.com | contactlensupdate.com | 60% | #2,199,905 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Tarsus Rx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Tarsus Rx (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tarsus Rx
Complete news archive for Tarsus Rx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tarsus Rx
Tarsus Rx was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Tarsus Rx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Bobak Azamian is the CEO of Tarsus Rx, as recorded in our data.
Tarsus Rx is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series B of $60M, raised on Jan 2020.
Tarsus Rx has 323 employees.
Annual revenue of Tarsus Rx is $451.36M as on Dec 31, 2025.
Tarsus was founded in 2017 and is headquartered in Irvine, United States. Focus is placed on the pharmaceutical sector, specifically ophthalmology, where proprietary drugs for eye conditions are developed. The lead candidate, TP-03, a topical ophthalmic treatment for Demodex blepharitis, is advancing through Phase 2b3 clinical trials. Additional pipeline efforts target other ocular disorders, with operations centered on drug innovation and testing.
Tarsus Rx offers XDEMVY, TP-04, and TP-05.
Yes, Tarsus Rx is publicly traded on NASDAQ under the ticker symbol TARS.
Tarsus Rx has 7 investors. Key investors include Frazier Healthcare Partners, Portage Biotech, Vivo Capital, Flying L Partners, and Visionary Ventures.
Tarsus Rx operates through Tarsus Pharmaceuticals, Inc..
Yes. Tarsus Rx was acquired by Portage Biotech in July 2022.